- ISIN
- US98422E1038
- CUSIP
- 98422E103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 21, 2018
Highlights
- Market Cap
- $1.23B
- Enterprise Value
- $1.16B
- EPS (TTM)
- $0.07
- PE Ratio
- 99.31
- Total Revenue (TTM)
- $314.85M
- Gross Profit (TTM)
- $187.04M
- EBITDA (TTM)
- $41.72M
- Year Range
- $4.52 - $10.08
- Target Price
- $9.00
- ROA (TTM)
- 3.06%
- ROE (TTM)
- 92.29%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XERS Performance Chart
Xeris Biopharma Holdings, Inc. (XERS) is down 12.1% since the beginning of the year. At $7 per share, XERS is trading 31.5% below its 52-week high of $10. Investors who bought $1,000 worth of XERS shares 5 years ago would now be looking at an investment worth $1,769.
Loading charts...
Returns By Period
Xeris Biopharma Holdings, Inc. (XERS) has returned -12.10% so far this year and 52.99% over the past 12 months.
Xeris Biopharma Holdings, Inc.
- 1D
- -0.72%
- 1M
- 11.47%
- YTD
- -12.10%
- 6M
- -4.30%
- 1Y
- 52.99%
- 3Y*
- 33.04%
- 5Y*
- 12.09%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
XERS Monthly Returns History
Based on dividend-adjusted daily data since Jun 21, 2018, XERS's average daily return is +0.09%, while the average monthly return is +1.56%. At this rate, an investment would double in approximately 3.7 years.
Historically, 54% of months were positive and 46% were negative. The best month was May 2020 with a return of +90.4%, while the worst month was Jun 2020 at -48.3%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 4 months.
On a daily basis, XERS closed higher 46% of trading days. The best single day was May 16, 2022 with a return of +29.2%, while the worst single day was Jun 25, 2020 at -48.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.24% | -16.85% | -5.23% | 5.60% | 0.57% | 12.01% | -12.10% | ||||||
| 2025 | 5.01% | 7.58% | 43.34% | -16.76% | 8.10% | -5.47% | 8.99% | 53.83% | 3.96% | 19.16% | -25.98% | 9.33% | 131.56% |
| 2024 | 4.68% | 25.00% | -28.13% | -20.81% | 28.86% | -0.22% | 10.22% | 13.31% | 1.42% | 12.98% | 1.86% | 3.35% | 44.26% |
| 2023 | -6.77% | 11.29% | 18.12% | 38.65% | 13.27% | 2.34% | -0.38% | -13.03% | -18.06% | -1.61% | 1.64% | 26.34% | 76.69% |
| 2022 | -27.99% | 12.80% | 7.56% | -4.69% | -9.43% | -30.32% | -7.79% | 17.61% | -6.59% | 2.56% | -6.25% | -11.33% | -54.61% |
| 2021 | 3.25% | 7.28% | -17.25% | -15.08% | -18.54% | 30.45% | -24.57% | -10.10% | -11.23% | -24.08% | 12.37% | 40.19% | -40.45% |
Benchmark Metrics
Xeris Biopharma Holdings, Inc. has an annualized alpha of 0.86%, beta of 1.47, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 21, 2018.
- This stock participated in 114.39% of S&P 500 Index downside but only 32.01% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 0.86%
- Beta
- 1.47
- R²
- 0.13
- Upside Capture
- 32.01%
- Downside Capture
- 114.39%
Return for Risk
Risk / Return Rank
XERS ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Xeris Biopharma Holdings, Inc. (XERS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XERS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.07 | ||
| Sortino ratioReturn per unit of downside risk | -1.13 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.37 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 1.14 | 2.78 | -1.64 |
| Martin ratioReturn relative to average drawdown | 2.00 | 12.44 | -10.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Xeris Biopharma Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Xeris Biopharma Holdings, Inc. was 96.22%, occurring on Jan 5, 2023. The portfolio has not yet recovered.
The current Xeris Biopharma Holdings, Inc. drawdown is 74.66%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -96.22%Jan 2023 | 4y 3mo | — | 7y 9moSep 2018 - now |
2018 correction2018 | -17.12%Aug 2018 | 8d | 12d | 20dJul 2018 - Aug 2018 |
2018 correction2018 | -10.98%Jul 2018 | 11d | 17d | 28dJun 2018 - Jul 2018 |
2018 pullback2018 | -7.87%Aug 2018 | 2d | 5d | 7dAug 2018 - Aug 2018 |
2018 pullback2018 | -3.41%Aug 2018 | 6d | 8d | 14dAug 2018 - Sep 2018 |
Drawdown Indicators
| XERS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.22% | -56.78% | -39.44% |
Max Drawdown (1Y)Largest decline over 1 year | -46.57% | -9.10% | -37.47% |
Max Drawdown (3Y)Largest decline over 3 years | -49.83% | -18.90% | -30.93% |
Max Drawdown (5Y)Largest decline over 5 years | -78.59% | -25.43% | -53.16% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -74.66% | -1.80% | -72.86% |
Average DrawdownAverage peak-to-trough decline | -78.99% | -10.71% | -68.28% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.55% | 2.03% | +24.52% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Xeris Biopharma Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Xeris Biopharma Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for XERS, comparing it with other companies in the Biotechnology industry. Currently, XERS has a P/E ratio of 99.3. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XERS relative to other companies in the Biotechnology industry. Currently, XERS has a P/S ratio of 3.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XERS in comparison with other companies in the Biotechnology industry. Currently, XERS has a P/B value of 94.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XERS
Add Xeris Biopharma Holdings, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XERS